NCT03598179 is a Phase 2 clinical trial of chimeric antigen receptor T cells in Lymphoma, B-Cell, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT03598179?

NCT03598179 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT03598179?

Interventions in NCT03598179: chimeric antigen receptor T cells.

What condition does NCT03598179 study?

NCT03598179 studies Lymphoma, B-Cell, Leukemia, B-cell.

Is NCT03598179 still recruiting?

NCT03598179 is currently status unknown. Last updated 7 August 2019.

Last reviewed 2019-08-07 · How we verify

NCT03598179

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Status unknown Phase 2 Last updated 7 August 2019

What this trial tests

Phase 2 trial testing chimeric antigen receptor T cells in Lymphoma, B-Cell in 10 participants. Status unknown.

Timeline

1 June 2018

Primary endpoint
30 December 2019

1 July 2020

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 June 2018
Primary completion	30 December 2019
Estimated completion	1 July 2020
Sites	1 location across China

Drugs / interventions tested

chimeric antigen receptor T cells — full drug profile →

Conditions studied

Lymphoma, B-Cell — all drugs for Lymphoma, B-Cell →
Leukemia, B-cell — all drugs for Leukemia, B-cell →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

18 and older, any sex, with Lymphoma, B-Cell or Leukemia, B-cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial is a single arm, single-center, non-randomized clinical trial which is designed to evaluate the efficacy and safety of XLCART001 in treatment of relapsed/refractory/high-risk B-cell malignancy subjects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, et al · · 2021 · cited 36× · PMID 34515338 · DOI 10.1002/14651858.cd013365.pub2

Verify or expand the search:

Other trials of chimeric antigen receptor T cells

Trials testing the same drug.

NCT03423992 — Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas · Phase 1 · unknown

Other recruiting trials for Lymphoma, B-Cell

Currently open trials in the same condition.

NCT06850285 — CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma · NA · recruiting
NCT06954805 — Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) · Phase 2 · recruiting
NCT06609304 — Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma · Phase 4 · recruiting
NCT06866873 — CD-19 CAR-T Cell for Pediatric ALL or Lymphoma · NA · recruiting
NCT06381830 — Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03598179 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 7 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03598179.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing